P-CAB类药物用于根除幽门螺杆菌的研究进展  

Research progress of P-CAB drugs in eradication of Helicobacter pylori

作　　者：曾钰杰 木叶赛尔·阿不都外力 聂占国 ZENG Yujie;MUYESAIER·Abuduwaili;NIE Zhanguo(Department of Gastroenterology,General Hospital of Xinjiang Military Region of the Chinese People′s Liberation Army,Urumqi 830000,China)

机构地区：[1]中国人民解放军新疆军区总医院消化内科,新疆乌鲁木齐830000

出　　处：《胃肠病学和肝病学杂志》2024年第9期1233-1236,共4页Chinese Journal of Gastroenterology and Hepatology

摘　　要：幽门螺杆菌(Helicobacter pylori,H.pylori)感染是全球发病率极高的传染性疾病之一,H.pylori与多种胃肠疾病密切相关,根除H.pylori可有效降低相关疾病感染风险。目前基于质子泵抑制剂的铋剂四联是临床上公认根除H.pylori的有效方案,现由于抑酸不足、抗生素耐药株增加等因素导致H.pylori根除率下降。一种新型钾离子竞争性酸阻滞剂(potassium-competitive acid blocker,P-CAB)的出现迎来转机,其高效且安全的抑酸优势可能会提高H.pylori的根除率。本文就目前临床上选用P-CAB根除H.pylori的临床研究进展作一综述。Helicobacter pylori(H.pylori)infection is one of the most H.pylori infectious disease in the world.H.pylori is closely associated with many gastrointestinal diseases.Eradication of H.pylori can effectively reduce the risk of infection.At present,the proton pump inhibitor bismuth-based quadruple therapy is considered to be an effective regimen for the eradication of H.pylori.Now because of the lack of acid inhibition,antibiotic resistance to increase and other factors leading to the reduction of H.pylori eradication rate.A new type of potassium-competitive acid blocker(P-CAB)is coming into being,which may improve the eradication rate of H.pylori.This article reviewed the clinical research progress of H.pylori eradication with P-CAB.

关 键 词：幽门螺杆菌 质子泵抑制剂 钾离子竞争性酸阻滞剂 根除 

分 类 号：R378[医药卫生—病原生物学]